Security
EyePoint, Inc. Common Stock · EYPT
EYPTNASDAQCommon stockCurrentCIK 1314102Updated Nov 2, 2026
Name history
EyePoint Pharmaceuticals, Inc. · through Dec 8, 2025pSivida Corp. · through Mar 30, 2018pSivida LTD · through Jun 18, 2008
EYPT price & chart
Loading TradingView…
NASDAQ:EYPT on TradingView ↗About the company
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint’s proprietary bioerodible Durasert E™ sustained-delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials for diabetic macular edema (DME).
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT ↗
Seeking Alpha
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens ↗
EyePoint: DME Upside Remains, But Financing Could Consume Most Of It (Rating Downgrade) ↗
EyePoint, Inc. (EYPT) Discusses LUCIA Phase III Topline Results for DURAVYU in Wet Age-Related Macular Degeneration - Slideshow ↗
SEC disclosures
EyePoint, Inc. files 8-K: Material Event ↗
Recent filings
SCHEDULE 13G - filed by TANG CAPITAL MANAGEMENT LLC regarding EyePoint, Inc.
Results of Operations and Financial Condition · Costs Associated with Exit or Disposal Activities · Other Events
Items 2.02, 2.05, 8.01, 9.01
Other Events
Items 8.01, 9.01
SCHEDULE 13G/A - filed by FEDERATED HERMES, INC. regarding EyePoint, Inc.
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 251,695,000Source | 300,917,000Source | 228,191,000Source | 301,147,000Source | 324,249,000Source | 288,217,000Source | 362,564,000Source | 329,247,000Source | 363,996,000Source | 418,465,000Source | 355,184,000Source | 180,356,000Source |
| Property, Plant and Equipment, NetUSD | 8,861,000Source | 8,391,000Source | 10,013,000Source | 8,762,000Source | 6,899,000Source | 9,482,000Source | 8,044,000Source | 6,677,000Source | 9,023,000Source | 8,177,000Source | 5,251,000Source | 1,360,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 74,577,000Source | 79,830,000Source | 110,458,000Source | 71,143,000Source | 90,769,000Source | 77,712,000Source | 85,158,000Source | 271,013,000Source | 101,821,000Source | 99,704,000Source | 281,263,000Source | 95,633,000Source |
| Inventory, NetUSD | 2,110,000Source | 2,807,000Source | 1,882,000Source | 2,678,000Source | 3,672,000Source | 1,250,000Source | 2,129,000Source | 4,257,000Source | 1,813,000Source | 2,305,000Source | 3,906,000Source | 2,886,000Source |
| Assets, CurrentUSD | 216,106,000Source | 268,549,000Source | 188,817,000Source | 265,251,000Source | 294,931,000Source | 249,504,000Source | 326,983,000Source | 317,709,000Source | 328,655,000Source | 383,306,000Source | 344,800,000Source | 172,808,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 8,929,000Source | 11,571,000Source | 6,377,000Source | 6,215,000Source | 9,636,000Source | 24,552,000Source | 6,218,000Source | 11,089,000Source | 20,105,000Source | 9,481,000Source | 9,039,000Source | 9,858,000Source |
| Operating Lease, Right-of-Use AssetUSD | 20,660,000Source | 21,405,000Source | 19,843,000Source | 21,089,000Source | 22,269,000Source | 19,777,000Source | 21,510,000Source | 4,711,000Source | 20,223,000Source | 21,000,000Source | 4,983,000Source | 6,038,000Source |
| Other Assets, NoncurrentUSD | 5,918,000Source | 2,422,000Source | 9,368,000Source | 5,895,000Source | — | 9,304,000Source | 5,877,000Source | — | 5,945,000Source | 5,832,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 51,513,000Source | 82,183,000Source | 61,780,000Source | 55,138,000Source | 95,944,000Source | 57,745,000Source | 64,168,000Source | 79,313,000Source | 57,883,000Source | 81,964,000Source | 88,861,000Source | 83,988,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 70,000Source | 53,000Source | 85,000Source | 69,000Source | 52,000Source | 83,000Source | 69,000Source | 50,000Source | 83,000Source | 68,000Source | 49,000Source | 34,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,037,369,000Source | -831,617,000Source | -1,284,280,000Source | -977,637,000Source | -802,256,000Source | -1,189,810,000Source | -918,211,000Source | -771,430,000Source | -1,104,978,000Source | -873,016,000Source | -742,146,000Source | -671,351,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 919,000Source | 1,171,000Source | 793,000Source | 832,000Source | 792,000Source | 802,000Source | 923,000Source | 836,000Source | 961,000Source | 1,028,000Source | 864,000Source | 786,000Source |
| Stockholders' Equity Attributable to ParentUSD | 200,182,000Source | 218,734,000Source | 166,411,000Source | 246,009,000Source | 228,305,000Source | 230,472,000Source | 298,396,000Source | 249,934,000Source | 306,113,000Source | 336,501,000Source | 266,323,000Source | 96,368,000Source |
| Additional Paid in Capital, Common StockUSD | 1,236,562,000Source | 1,049,127,000Source | 1,449,813,000Source | 1,222,745,000Source | 1,029,717,000Source | 1,419,397,000Source | 1,215,615,000Source | 1,020,478,000Source | 1,410,047,000Source | 1,208,421,000Source | 1,007,556,000Source | 766,899,000Source |
| Liabilities and EquityUSD | 251,695,000Source | 300,917,000Source | 228,191,000Source | 301,147,000Source | 324,249,000Source | 288,217,000Source | 362,564,000Source | 329,247,000Source | 363,996,000Source | 418,465,000Source | 355,184,000Source | 180,356,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 30,094,000Source | 48,794,000Source | 41,943,000Source | 33,175,000Source | 62,102,000Source | 37,460,000Source | 41,677,000Source | 62,580,000Source | 37,024,000Source | 49,048,000Source | 63,263,000Source | 34,537,000Source |
| Operating Lease, Liability, CurrentUSD | 1,961,000Source | 1,188,000Source | 2,553,000Source | 1,900,000Source | 1,130,000Source | 2,084,000Source | 1,768,000Source | 1,098,000Source | 2,022,000Source | 1,247,000Source | 563,000Source | 543,000Source |
| Accounts Payable, CurrentUSD | 10,076,000Source | 7,343,000Source | 17,267,000Source | 19,685,000Source | 14,296,000Source | 18,813,000Source | 16,419,000Source | 7,082,000Source | 10,490,000Source | 11,721,000Source | 6,504,000Source | 5,919,000Source |
| Operating Lease, Liability, NoncurrentUSD | 21,301,000Source | 21,922,000Source | 19,814,000Source | 21,815,000Source | 22,164,000Source | 20,230,000Source | 22,314,000Source | 4,624,000Source | 20,772,000Source | 21,858,000Source | 4,906,000Source | 5,984,000Source |
| Other Liabilities, NoncurrentUSD | 118,000Source | 233,000Source | 23,000Source | 148,000Source | — | 55,000Source | 177,000Source | — | 87,000Source | 205,000Source | — | 600,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 17,943,000Source | 14,166,000Source | 21,997,000Source | 11,478,000Source | 13,341,000Source | 16,441,000Source | 18,178,000Source | 15,940,000Source | 24,394,000Source | 18,103,000Source | 17,521,000Source | 16,359,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 204,000,000Source | 253,800,000Source | 180,500,000Source | 255,700,000Source | 280,200,000Source | 222,500,000Source | 318,200,000Source | 299,300,000Source | 306,100,000Source | 370,900,000Source | 331,000,000Source | 144,600,000Source |
| Deferred Revenue, CurrentUSD | — | 25,996,000Source | — | 0Source | 33,335,000Source | — | 5,115,000Source | 38,377,000Source | 0Source | 17,784,000Source | 38,592,000Source | 1,205,000Source |
| Deferred Revenue, NoncurrentUSD | 0Source | 11,234,000Source | — | 0Source | 11,678,000Source | — | 0Source | 12,109,000Source | 0Source | 10,853,000Source | 20,692,000Source | 13,557,000Source |
| Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 30,000,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 29,310,000Source |
cash flow · annual statements
| Line item | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -231,962,000Source | -130,870,000Source | -70,795,000Source | -102,254,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | 2,309,000Source | 1,540,000Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | — | 27,873,000Source | 36,740,000Source | 12,057,000Source | 14,177,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | — | -492,000Source | -1,600,000Source | 1,553,000Source | 760,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 279,000Source | 90,000Source | 83,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | — | — | -240,110,000Source | -126,226,000Source | 1,875,000Source | -65,005,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | 68,580,000Source | -219,355,000Source | -3,315,000Source | -17,265,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 3,280,000Source | 4,052,000Source | 3,483,000Source | 2,150,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | 1,388,000Source | 4,512,000Source | 169,000Source | 295,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 173,647,000Source | 164,022,000Source | 187,070,000Source | -690,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | 30,000,000Source | 38,235,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | 2,117,000Source | -181,559,000Source | 185,630,000Source | -82,960,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 101,971,000Source | 99,854,000Source | 281,413,000Source | 95,783,000Source | 178,743,000Source | 45,059,000Source | 22,364,000Source | 45,411,000Source | 101,971,000Source | 99,854,000Source | 281,413,000Source | 95,783,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | 0Source | 1,405,000Source | 2,600,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 200,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | 27,873,000Source | 36,740,000Source | 12,057,000Source | 14,177,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 2,050,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | 306,100,000Source | 370,900,000Source | 331,000,000Source | 144,600,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 2,100,000Source | 1,540,000Source | 464,000Source | 396,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | -1,347,000Source | -1,559,000Source |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | 51,610,000Source | 52,358,000Source | 40,102,000Source | 34,817,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 20,699,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 279,000Source | 90,000Source | 83,000Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | — | — | — | — | — | — | 33,000Source | 14,000Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | — | 0Source | 693,000Source | 1,949,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | — | — | — | — | — | -231,962,000Source | -130,870,000Source | -70,795,000Source | -102,254,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | 11,751,000Source | 15,074,000Source | 4,355,000Source | -2,617,000Source |
| Operating ExpensesUSD | — | — | — | — | — | — | — | — | 274,805,000Source | 189,127,000Source | 121,085,000Source | 141,041,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 1,200,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | 11,784,000Source | 15,088,000Source | 6,949,000Source | 2,131,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 173,445,000Source | 163,314,000Source | 226,174,000Source | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 30,000,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | — | — | — | — | — | 124,000,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | — | 395,000Source |
income statement · annual statements
| Line item | Q4 2018 | Q4 2017 | Q3 2018 | Q3 2017 | Q2 2018 | Q2 2017 | Q1 2019 | Q1 2018 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 928,000Source | 590,000Source | 933,000Source | 5,971,000Source | 486,000Source | 385,000Source | 31,371,000Source | 43,273,000Source | 46,018,000Source | 41,404,000Source |
| Operating Income (Loss)USD | — | — | -4,678,000Source | -5,160,000Source | -5,808,000Source | -94,000Source | -13,554,000Source | -6,006,000Source | -243,434,000Source | -145,854,000Source | -75,067,000Source | -99,637,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 25,000Source | 20,000Source | 26,000Source | 27,000Source | 129,000Source | 23,000Source | 11,784,000Source | 15,088,000Source | 6,949,000Source | 2,131,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | -5,140,000Source | — | -67,000Source | — | — | -231,683,000Source | -130,780,000Source | -70,712,000Source | -102,254,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 279,000Source | 90,000Source | 83,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -6,978,000Source | -5,140,000Source | -5,782,000Source | -67,000Source | -33,126,000Source | -5,983,000Source | -231,962,000Source | -130,870,000Source | -70,795,000Source | -102,254,000Source |
| Earnings Per Share, BasicUSD per share | — | — | — | — | — | — | — | — | -3.17Source | -2.32Source | -1.82Source | -2.74Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | — | — | — | — | -3.17Source | -2.32Source | -1.82Source | -2.74Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | — | — | — | — | — | 73,251Source | 56,298Source | 38,904,000Source | 37,317,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | — | — | — | — | 73,251Source | 56,298Source | 38,904,000Source | 37,317,000Source |
| Interest Expense (non-operating)USD | — | — | — | — | — | — | — | — | 33,000Source | 14,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 0Source | 180,000Source | 183,000Source | 180,000Source | 615,000Source | 182,000Source | — | — | 0Source | 2,050,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | 2,309,000Source | 1,540,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 2,281,000Source | 2,426,000Source | 2,472,000Source | 2,900,000Source | 4,161,000Source | 2,572,000Source | 51,610,000Source | 52,358,000Source | 40,102,000Source | 34,817,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -231,783,000Source | -130,880,000Source | -70,812,000Source | -102,354,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | 815,000Source | 0Source | — | — | 1,247,000Source | 3,189,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | 11,751,000Source | 15,074,000Source | 4,355,000Source | -2,617,000Source |
| Operating ExpensesUSD | — | — | 5,606,000Source | 5,750,000Source | 6,741,000Source | 6,065,000Source | 14,040,000Source | 6,391,000Source | 274,805,000Source | 189,127,000Source | 121,085,000Source | 141,041,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 1,200,000Source |
| Research and Development ExpenseUSD | — | — | 3,325,000Source | 3,324,000Source | 4,269,000Source | 3,165,000Source | 6,233,000Source | 3,819,000Source | 221,039,000Source | 132,926,000Source | 64,662,000Source | 49,642,000Source |
| Selling and Marketing ExpenseUSD | — | — | — | — | — | — | 3,646,000Source | 0Source | 90,000Source | 131,000Source | 11,689,000Source | 25,507,000Source |
| Gain (Loss) on Derivative Instruments, Net, Pretax | — | — | —Source | —Source | — | — | —Source | —Source | — | — | — | — |
Filing attachments
ex99_1.htm · SCHEDULE 13G · 2026-10-27
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.001, of EyePoint, Inc. and further agree to the filing of this agreement as an exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its…
Read attachment ↗eypt-ex99_1.htm · 8-K · 2026-10-19
Exhibit 99.1 EyePoint Announces Strategic Prioritization WATERTOWN, Mass., October 19, 2026 (GLOBE NEWSWIRE) - EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced a strategic prioritization designed to reduce operating expenses and focus resources on its late-stage program for DURAVYU™ in diabetic macular edema (DME). This strategic realignment follows today’…
Read attachment ↗eypt-ex99_1.htm · 8-K · 2026-10-19
Exhibit 99.1 EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYUTM in Wet AMD - LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement - - Key secondary endpoints in LUCIA were met including a superior 38% reduction in treatment burden (nominal p-value <0.0001), with 52% of eyes supplement-free and 71% receiving zero or one sup…
Read attachment ↗eypt-ex99_2.htm · 8-K · 2026-10-19
LUCIA Phase 3 Clinical Trial DURAVYU in Wet AMD Topline Results | October 2026 Exhibit 99.2 Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, are forward-looking sta…
Read attachment ↗eypt-ex99_1.htm · 8-K · 2026-09-10
EX-99.1 2 eypt-ex99_1.htm EX-99.1 LUGANO Phase 3 Clinical Trial DURAVYU in Wet AMD Expanded Results & Analyses | September 2026 Exhibit 99.1 Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or bel…
Read attachment ↗eypt-ex99_1.htm · 8-K · 2026-08-17
EX-99.1 2 eypt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYUTM 2.7mg in Wet AMD - DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15 letters) unrelated to wet AMD; primary endpoint not achieved in full dataset, confounded by this asymmetric cohort - …
Read attachment ↗